You Are Here    Home   News

News
Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease
by Liz Highleyman, 2014-04-16 18:00
Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and people who experience severe hepatitis recurrence after a liver transplant, researchers reported last week at the 49th Annual Meeting of the European Association for the Study of

Abolishing HIV in Rwanda
by Gus Cairns, 2014-04-16 13:00
The achievement of universal HIV coverage in one African country, Rwanda, has resulted in HIV diagnoses more than halving and annual incidence falling by 90%, the 2014 Treatment as Prevention workshop in Vancouver heard earlier this month. Edward Mills of the British Columbia Centre for Excellence in HIV/AIDS, which runs a clinic in Rwanda, told

Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B
by Liz Highleyman, 2014-04-16 11:20
Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in people with HBeAg-positive chronic hepatitis B, as did added interferon after long-term nucleoside therapy, but adding interferon after only a short course of antivirals did not improve response, according to a set

AbbVie 3-drug combination cures 92%-96% of cirrhotic hepatitis C patients
by Keith Alcorn, 2014-04-15 09:10
The largest study of new direct-acting antivirals yet conducted in hepatitis C genotype 1 patients with compensated cirrhosis has shown that it is possible to cure between 92% and 96% of patients with cirrhosis, regardless of previous treatment history, within 12 to 24 weeks, according to results of the TURQUOISE-II study presented at the

AbbVie 3-drug combination cures 92 to 96% of hepatitis C patients with cirrhosis
by Keith Alcorn, 2014-04-15 09:10
The largest study of new direct-acting antivirals yet conducted in people with hepatitis C genotype 1 who have compensated cirrhosis has shown that it is possible to cure between 92 and 96% of people with cirrhosis, regardless of previous treatment history, within 12 to 24 weeks, according to results of the TURQUOISE-II study presented

AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C
by Keith Alcorn, 2014-04-14 17:40
A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, Christophe H├ęzode reported on Friday at the 49th Annual Meeting of the European Association for the Study of the Liver in London. Genotype 4 hepatitis C is the predominant form

Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients
by Liz Highleyman, 2014-04-14 11:30
A co-formulation of sofosbuvir and ledipasvir taken for as little as eight weeks produced high sustained response rates across the board for participants in the phase 3 ION trials, including people with genotype 1 hepatitis C virus (HCV) starting treatment for the first time, prior non-responders and people with liver cirrhosis, according to findings

Sofosbuvir/ledipasvir coformulation cures more than 90% of treatment-naive and retreated genotype 1 patients
by Liz Highleyman, 2014-04-14 11:30
A coformulation of sofosbuvir and ledipasvir taken for as little as 8 weeks produced high sustained response rates across the board for participants in the phase 3 ION trials, including people with HCV genotype 1 starting treatment for the first time, prior non-responders and people with liver cirrhosis, according to findings presented last week

Sofosbuvir + simeprevir dual therapy shows high cure rates for hepatitis C patients with or without cirrhosis
by Liz Highleyman, 2014-04-14 11:20
A 12-week oral regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) without pegylated interferon or ribavirin led to sustained virological response in 93% of genotype 1 hepatitis C patients with either absent to moderate liver fibrosis or with advanced fibrosis or cirrhosis, according to data from the COSMOS trial presented last week at the 49th

European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs
by Keith Alcorn, 2014-04-12 00:10
The European Association for the Study of the Liver has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals.EASL is also encouraging European physicians to combine products from different pharmaceutical companies to achieve the most potent interferon-free regimens,

European liver specialists recommend `mix-and-match` approach to new hepatitis C drugs
by Keith Alcorn, 2014-04-12 00:10
The European Association for the Study of the Liver has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals.EASL is also encouraging European physicians to combine products from different pharmaceutical companies to achieve the most potent interferon-free regimens,

Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection
by Liz Highleyman, 2014-04-11 08:30
Treatment for 12 weeks with a co-formulation of sofosbuvir and ledipasvir led to sustained response for all participants with HIV and HCV co-infection who had genotype 1 hepatitis C virus (HCV) followed for 12 weeks post-treatment, according to interim findings from the ERADICATE study presented on Thursday at the 49th Annual Meeting of the

Sofosbuvir/ledipasvir produces early cure for 100% of HIV/HCV coinfected patients
by Liz Highleyman, 2014-04-11 08:30
Treatment for 12 weeks with a coformulation of sofosbuvir and ledipasvir led to sustained response for all HIV/HCV coinfected patients with genotype 1 hepatitis C followed for 12 weeks post-treatment, according to interim findings from the ERADICATE study presented  Thursday at the 49th EASL International Liver Congress in London. Anu Osinusi from the U.S.

Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients
by Liz Highleyman, 2014-04-11 08:20
A coformulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, patients with decompensated cirrhosis and people who were not cured with previous sofosbuvir-containing therapy, according to a series of studies presented Thursday at the 49th EASL International Liver Congress in London. Edward Gane

88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy
by Keith Alcorn, 2014-04-10 22:20
Almost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with the protease inhibitor simeprevir (Olysio) combined with pegylated interferon and ribavirin, the 49th Annual Meeting of the European Association for the Study of the Liver heard on

AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections
by Keith Alcorn, 2014-04-10 17:10
A 12-week course of three direct-acting antivirals developed by AbbVie, plus ribavirin, cured 96.3% of treatment-experienced patients with hepatitis C genotype 1 infection, Professor Stefan Zeuzem of the J.W. Goethe University Hospital, Frankfurt, Germany told the 49th Annual Meeting of the European Association for the Study of the Liver in London on Thursday. The AbbVie combination

Can we provide point-of-care viral load tests in poor countries?
by Gus Cairns, 2014-04-10 16:40
It is not impossible to provide mobile, point-of-care viral load tests in resource-poor settings, the 2014 Treatment as Prevention workshop in Vancouver heard last week. By using a number of techniques including sample pooling, high throughput, and training-up lay testers, it should be possible to provide a viral load for not much more than the cost